VAL.LSE ValiRx plc

Healthcare Biotechnology London Exchange
0.0017 GBX
Close of Oct 30, 2026
0.1200 0.4800
Market cap
GBX 2.24M
P/E
-
P/B
0.72x
ROE
-95.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is VAL.LSE undervalued?

Graham number

The Graham number of ValiRx plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ValiRx plc fundamental analysis

No fundamental analysis for ValiRx plc yet.

ValiRx plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ValiRx plc

ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical t…

Full company profile